Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhapontigenin is a naturally occurring stilbenol, structurally related to resveratrol, found in plants such as Rheum undulatum (rhubarb) and Gnetum hainanense. It is characterized chemically as trans-stilbene substituted with hydroxy groups at positions 3 and 5 on one phenyl ring, and a hydroxy group at position 3 plus a methoxy group at position 4 on the other phenyl ring. Rhapontigenin exhibits multiple biological activities including inhibition of cytochrome P450 enzymes (notably CYP1A1), antineoplastic (anticancer), antioxidant, antiviral, antifungal, antibacterial, antilipemic (lipid-lowering), cardioprotective effects, angiogenesis inhibition, melanin synthesis inhibition, radical scavenging activity and quorum sensing inhibition. It has been studied for its cytotoxic effects against cancer cells—particularly colon cancer—and for its potential use in improving cardiovascular health due to its structural similarity to phytoestrogens like resveratrol and diethylstilbestrol. Its mechanism of action includes selective inactivation of cytochrome P450 enzymes; it may also act as a phytoestrogen due to structural similarities with estrogenic compounds[1][2][3][4][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rhapontigenin.